NO985484D0 - FremgangsmÕte og preparat for behandling og forhindring av hyperurikemi - Google Patents

FremgangsmÕte og preparat for behandling og forhindring av hyperurikemi

Info

Publication number
NO985484D0
NO985484D0 NO985484A NO985484A NO985484D0 NO 985484 D0 NO985484 D0 NO 985484D0 NO 985484 A NO985484 A NO 985484A NO 985484 A NO985484 A NO 985484A NO 985484 D0 NO985484 D0 NO 985484D0
Authority
NO
Norway
Prior art keywords
hyperuricemia
prevention
preparation
treatment
Prior art date
Application number
NO985484A
Other languages
English (en)
Other versions
NO985484L (no
Inventor
Toshihiko Fujiwara
Koichi Iwasaki
Hiroyoshi Horikoshi
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of NO985484D0 publication Critical patent/NO985484D0/no
Publication of NO985484L publication Critical patent/NO985484L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO985484A 1997-11-25 1998-11-24 FremgangsmÕte og preparat for behandling og forhindring av hyperurikemi NO985484L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP32318297 1997-11-25

Publications (2)

Publication Number Publication Date
NO985484D0 true NO985484D0 (no) 1998-11-24
NO985484L NO985484L (no) 1999-05-26

Family

ID=18151987

Family Applications (1)

Application Number Title Priority Date Filing Date
NO985484A NO985484L (no) 1997-11-25 1998-11-24 FremgangsmÕte og preparat for behandling og forhindring av hyperurikemi

Country Status (23)

Country Link
US (1) US6353009B1 (no)
EP (1) EP0919232B1 (no)
KR (1) KR19990045531A (no)
AR (1) AR011231A1 (no)
AT (1) ATE278400T1 (no)
AU (1) AU744653B2 (no)
BR (1) BR9805012A (no)
CA (1) CA2254394C (no)
CZ (1) CZ378898A3 (no)
DE (2) DE69826811D1 (no)
ES (1) ES2230657T3 (no)
HK (1) HK1020259A1 (no)
HU (2) HUP9902721A2 (no)
ID (1) ID21332A (no)
IL (1) IL127219A (no)
NO (1) NO985484L (no)
NZ (1) NZ332895A (no)
PL (1) PL329893A1 (no)
RU (1) RU2190425C2 (no)
SA (1) SA99191266A (no)
TR (1) TR199802441A3 (no)
TW (1) TW592697B (no)
ZA (1) ZA9810788B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69919707T2 (de) 1998-06-19 2005-09-01 Chiron Corp., Emeryville Glycogen synthase kinase 3 inhibitoren
DK1180686T3 (da) * 1999-05-27 2010-01-04 Cmic Co Ltd Lægemidler til nyresygdomme og fremgangsmåde til screening deraf
US6784199B2 (en) 2000-09-21 2004-08-31 Aryx Therapeutics Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, and atherosclerosis in mammals
US6680387B2 (en) 2000-04-24 2004-01-20 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6768008B2 (en) 2000-04-24 2004-07-27 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6958355B2 (en) 2000-04-24 2005-10-25 Aryx Therapeutics, Inc. Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
WO2003075921A2 (en) 2002-03-05 2003-09-18 Transtech Pharma, Inc. Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
CA2522275A1 (en) * 2003-05-20 2005-01-06 Transtech Pharma, Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
US20050025823A1 (en) * 2003-07-29 2005-02-03 Fong Andy A.T. Methods of use of herbal compositions
JP2005092923A (ja) * 2003-09-12 2005-04-07 Renesas Technology Corp 半導体記憶装置
US8557831B2 (en) * 2004-07-21 2013-10-15 University Of Florida Research Foundation, Inc. Compositions and methods for treatment and prevention of insulin resistance
JP2009501795A (ja) * 2005-07-21 2009-01-22 ユニバーシティ オブ フロリダ リサーチファウンデーション インコーポレイティッド 高尿酸血に関連する健康状態の治療及び予防のための組成物及び方法
NZ580588A (en) * 2007-04-05 2011-12-22 Daiichi Sankyo Co Ltd Fused bicyclic heteroaryl derivatives
EP2404918B1 (en) 2009-03-05 2016-11-30 Daiichi Sankyo Company, Limited Pyridine derivative as ppary inhibitor
TWI517850B (zh) 2009-09-30 2016-01-21 Ｖｔｖ治療有限責任公司 經取代之咪唑衍生物及其使用方法
US8822464B2 (en) 2011-11-28 2014-09-02 Boehringer Ingelheim International Gmbh N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8741892B2 (en) 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8846948B2 (en) 2011-12-13 2014-09-30 Boehringer Ingelheim International Gmbh Compounds
US8796467B2 (en) 2011-12-13 2014-08-05 Boehringer Ingelheim International Gmbh Compounds
US8883789B2 (en) 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8716277B2 (en) * 2011-12-14 2014-05-06 Boehringer Ingelheim International Gmbh Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
US8937176B2 (en) 2011-12-14 2015-01-20 Boehringer Ingelheim International Gmbh Compounds
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
WO2013111870A1 (ja) * 2012-01-27 2013-08-01 帝人ファーマ株式会社 糖尿病の治療薬
CN105283559A (zh) 2013-05-22 2016-01-27 端粒诊断公司 短端粒丰度的量度
US20190152967A1 (en) * 2016-04-04 2019-05-23 The Schepens Eye Research Institute, Inc. Peroxisome proliferator-activated receptor gamma selective agonists for inhibition of retinal pigment epithelium degeneration or geographic atrophy

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS58118577A (ja) 1982-01-07 1983-07-14 Takeda Chem Ind Ltd チアゾリジン誘導体
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
HU210339B (en) 1985-05-21 1995-03-28 Pfizer Process for preparing thiazolidinediones and their pharmaceutical compositions haring hypoglycemic effect
ZA873745B (en) 1986-06-04 1988-10-26 Daiichi Seiyaku Co Benzopyran derivatives
US4873255A (en) 1987-02-04 1989-10-10 Sankyo Company Limited Thiazolidinone derivatives, their preparation and their use
FI91869C (fi) 1987-03-18 1994-08-25 Tanabe Seiyaku Co Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
EP0295828A1 (en) 1987-06-13 1988-12-21 Beecham Group Plc Novel compounds
US5194443A (en) 1987-09-04 1993-03-16 Beecham Group P.L.C. Compounds
US5260445A (en) 1987-09-04 1993-11-09 Beecham Group P.L.C. 2,4-thiazolidinediones
DE10199003I1 (de) 1987-09-04 2003-06-12 Beecham Group Plc Substituierte Thiazolidinionderivate
US5232925A (en) 1987-09-04 1993-08-03 Beecham Group P.L.C. Compounds
WO1989008650A1 (en) 1988-03-08 1989-09-21 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US5120754A (en) 1988-03-08 1992-06-09 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US5223522A (en) 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
WO1989008651A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
US5155114A (en) * 1989-01-23 1992-10-13 Fujisawa Pharmaceutical Company, Ltd. Method of treatment using pyrazolopyridine compound
US4897405A (en) 1989-04-21 1990-01-30 American Home Products Corporation Novel naphthalenylalkyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
GB8919434D0 (en) 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
WO1991007107A1 (en) 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
JPH0469383A (ja) 1990-07-06 1992-03-04 Yamanouchi Pharmaceut Co Ltd 置換チアゾリジン誘導体
GB9017218D0 (en) 1990-08-06 1990-09-19 Beecham Group Plc Novel compounds
ATE152464T1 (de) * 1992-07-02 1997-05-15 Novo Nordisk As Polymerisation von lignin bei alkalischem ph-wert
GB9223059D0 (en) 1992-11-04 1992-12-16 Bamford Excavators Ltd Intercooler apparatus
JP2845743B2 (ja) 1992-12-28 1999-01-13 三菱化学株式会社 新規なナフタレン誘導体
JPH06211657A (ja) 1993-01-21 1994-08-02 Mochida Pharmaceut Co Ltd 尿酸***剤
ATE376829T1 (de) 1993-09-15 2007-11-15 Daiichi Sankyo Co Ltd Verwendung von thiazolidindionen zur vorbeugung oder verzögerung des auftretens des nichtinsulinabhängigen diabetes mellitus (niddm)
DK0684242T3 (da) * 1993-12-27 1999-11-01 Japan Tobacco Inc Isoxazolidindionderivat og anvendelse deraf
CZ289317B6 (cs) 1994-04-11 2002-01-16 Sankyo Company Limited Heterocyklická sloučenina, farmaceutický prostředek ji obsahující a její pouľití
CA2159938A1 (en) * 1994-10-07 1996-04-08 Hiroaki Yanagisawa Oxime derivatives, their preparation and their therapeutic use
CZ293016B6 (cs) 1995-06-01 2004-01-14 Sankyo Company Limited Benzimidazolové deriváty a farmaceutické prostředky s jejich obsahem
US5929055A (en) * 1997-06-23 1999-07-27 The Research Foundation Of State University Of New York Therapeutic method for management of diabetes mellitus

Also Published As

Publication number Publication date
DE69826811D1 (de) 2004-11-11
PL329893A1 (en) 1999-06-07
TW592697B (en) 2004-06-21
AR011231A1 (es) 2000-08-02
NO985484L (no) 1999-05-26
SA99191266A (ar) 2005-12-03
IL127219A0 (en) 1999-09-22
CA2254394C (en) 2009-11-17
ATE278400T1 (de) 2004-10-15
DE69826811T4 (de) 2006-09-21
ES2230657T3 (es) 2005-05-01
AU9410298A (en) 1999-06-17
TR199802441A2 (xx) 1999-10-21
HUP9902721A2 (hu) 1999-12-28
DE69826811T2 (de) 2005-06-16
ZA9810788B (en) 1999-05-25
US6353009B1 (en) 2002-03-05
CA2254394A1 (en) 1999-05-25
TR199802441A3 (tr) 1999-10-21
AU744653B2 (en) 2002-02-28
HK1020259A1 (en) 2000-04-07
NZ332895A (en) 2001-04-27
ID21332A (id) 1999-05-27
HUP9802721A1 (hu) 2000-03-28
EP0919232A1 (en) 1999-06-02
RU2190425C2 (ru) 2002-10-10
KR19990045531A (ko) 1999-06-25
HU9802721D0 (en) 1999-01-28
EP0919232B1 (en) 2004-10-06
BR9805012A (pt) 2000-03-21
IL127219A (en) 2001-08-08
CZ378898A3 (cs) 1999-07-14

Similar Documents

Publication Publication Date Title
NO985484L (no) FremgangsmÕte og preparat for behandling og forhindring av hyperurikemi
NO994613D0 (no) Fremgangsmaate og preparat til behandling av sövn-apne
NO20004098L (no) FremgangsmÕter og preparater for behandling av makrofag- formidlede lidelser
NO994778L (no) Fremgangsmåter og preparater for behandling av inflammatorisk tarmsyndrom
NO971015D0 (no) Forbindelser og metoder for behandling av cancer
DK1041879T3 (da) Desinfektionsmiddel og fremstillingsmetode
NO961006D0 (no) Fosfonomononukleinsyrer, fremgangsmåter for fremstilling derav og anvendelse av forbindelsene
NO20015542L (no) Fremgangsmåte for fremstilling og anvendelse av N- desmetylzopikloner
NO983641D0 (no) Fremgangsmåte til behandling og farmasöytisk preparat
NO20012963D0 (no) Fremgangsmåte for fremstilling av 3-alkanoylindoler og 3- alkylindoler
NO20003070L (no) Substituert tiazolidinderivat, fremgangsmÕte for fremstilling og anvendelse derav
FI980246A (fi) Menetelmä keittimen käyttämiseksi ja keitin
NO20003229L (no) Kombinasjon av benzosykloheptapyridinforbindelser og antineoplastiske midler for behandling av proliferaktive sykdommer
NO983512D0 (no) Midler for behandling og forhindring av AIDS
NO972426D0 (no) Metode for anvendelse av triarylethylenderivater ved behandling og forhindring av osteoporose
NO20000706D0 (no) Metode for økning av biotilgjengeligheten av feksofenadin og dens derivater
NO20010464L (no) FremgangsmÕter og preparater for behandling av gastro- øsofagealt-reflukssyndrom
NO20001758D0 (no) Fremgangsmåter og blandinger for behandling av leddgikt
NO20020369D0 (no) Preparat for forebyggelse og behandling av nyredysfunksjon og -sykdommer
NO20012099D0 (no) Fremgangsmåte for fremstilling av 4-arylpiperidin-3- carbinoler og beslektede forbindelser
NO20022990D0 (no) Fremgangsmåte og sammensetning for behandling av smerte
NO20022984L (no) Forbindelse og fremgangsmåte for behandling av smerte
NO990185D0 (no) FremgangsmÕte for fremstilling av naftypyridoner og mellomprodukter
DK1047668T3 (da) Triazepinoner, fremgangsmåde til fremstilling deraf og terapeutisk anvendelse deraf
UA25504A (uk) Спосіб лікуваhhя дисбактеріозу hосоглотки

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application